  | Mouraux, C., Dangouloff, T., Poleur, M., Mackels, L., Vanden Brande, L., Daron, A., Servais, L., Maertens de Noordhout, A., & DELSTANCHE, S. (2024). Epidemiological study and diagnostic approach analysis of Neuromuscular population of Neuromuscular Reference Center of Liege, Belgium [Poster presentation]. BeSHG annual symposium 2024, Belgium.  Peer reviewed |
 | Dangouloff, T., Thokala, P., Stevenson, M. D., Deconinck, N., D'Amico, A., Daron, A., DELSTANCHE, S., Servais, L., & Hiligsmann, M. (02 December 2023). Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium. Neuromuscular Disorders, 34, 61-67. doi:10.1016/j.nmd.2023.11.013 Editorial reviewed |
 | Vincent-Genod, D., Rippert, P., Coton, J., Le Goff, L., Barriere, A., Berruyer, A., Bernard, M., Garde, C., Gutierrez-Garcia, M., Gilabert, S., Gomes-Lisboade-Souza, A., Daron, A., Servais, L., Thomann, G., & Vuillerot, C. (26 October 2023). Scoring People With Spinal Muscular Atrophy on the Motor Function Measure Using the Microsoft Kinect. Pediatric Physical Therapy, 35 (1), 36-41. doi:10.1097/PEP.0000000000000968 Peer Reviewed verified by ORBi |
  | Monseur, A., Carlin, B. P., Boulanger, B., Seferian, A., Servais, L., Freitag, C., Thielemans, L., Gidaro, T., Gargaun, E., Chê, V., Schara, U., Gangfuß, A., D’Amico, A., Dowling, J. J., Darras, B. T., Daron, A., Hernandez, A., de Lattre, C., Arnal, J.-M., ... the NatHis-MTM Study Group. (July 2022). Leveraging Natural History Data in One- and Two-Arm Hierarchical Bayesian Studies of Rare Disease Progression. Statistics in Biosciences, 14 (2), 237 - 258. doi:10.1007/s12561-021-09323-5 Peer Reviewed verified by ORBi |
 | Mercuri, E., Deconinck, N., Mazzone, E. S., Nascimento, A., Oskoui, M., Saito, K., Vuillerot, C., Baranello, G., Boespflug-Tanguy, O., Goemans, N., Kirschner, J., Kostera-Pruszczyk, A., Servais, L., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R. S., Staunton, H., ... Daron, A. (April 2022). Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Neurology, 21 (1), 42-52. doi:10.1016/S1474-4422(21)00367-7 Peer Reviewed verified by ORBi |
 | Hustinx, M., Poleur, M., Daron, A., Maertens De Noordhout, A., Servais, L., & Delstanche, S. (2022). Overlap Between Hereditary Sensory- Motor Neuropathy (HSMN) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Journal of Neuromuscular Diseases. Peer Reviewed verified by ORBi |
 | Annoussamy, M., Eggenspieler, D., Seferian, A., Mercuri, E., Straub, V., Muntoni, F., Scoto, M., Poleur, M., Daron, A., Butoianu, N., Mirea, A., Goemans, N., Previtali, S., Tulinius, M., Nascimento, A., Heydemann, P., Panzara, M., Singh, T., Strijbos, P., & Servais, L. (2022). Application for primary endpoint qualification of the 95th centile of stride velocity (SV95C) in Duchenne muscular dystrophy. Neuromuscular Disorders. doi:10.1016/j.nmd.2022.07.099 Peer Reviewed verified by ORBi |
 | Poleur, M., Annoussamy, M., Eggenspieler, D., DELSTANCHE, S., DARON, A., & Servais, L. (October 2021). Longitudinal follow-up of adult patients with spinal muscular atrophy undergoing nusinersen treatment using an innovative magneto-inertial device. Neuromuscular Disorders, 31, 130. doi:10.1016/j.nmd.2021.07.290 Peer Reviewed verified by ORBi |
 | Poleur, M., Ulinici, A., DARON, A., Schneider, O., Farra, F. D., Demonceau, M., Annoussamy, M., Vissière, D., Eggenspieler, D., & Servais, L. (October 2021). Actimyo®: Normative data in a non-controlled environment. Neuromuscular Disorders, 31, 86-S87. doi:10.1016/j.nmd.2021.07.149 Peer Reviewed verified by ORBi |
 | Poleur, M., Ulinici, A., DARON, A., Schneider, O., Dal Farra, F., Demonceau, M., Annoussamy, M., Vissière, D., Eggenspieler, D., & Servais, L. (2021). Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment. Orphanet Journal of Rare Diseases. doi:10.1186/s13023-021-01956-5 Peer Reviewed verified by ORBi |
| Servais, L., Baranello, G., Scoto, M., DARON, A., & Oskoui, M. (May 2021). Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities. Expert Opinion on Investigational Drugs, 30 (5), 519-527. doi:10.1080/13543784.2021.1904889 Peer Reviewed verified by ORBi |
 | Annoussamy, M., Seferian, A. M., DARON, A., Péréon, Y., Cances, C., Vuillerot, C., De Waele, L., Laugel, V., Schara, U., Gidaro, T., Lilien, C., Hogrel, J.-Y., Carlier, P., Fournier, E., Lowes, L., Gorni, K., Ly-Le Moal, M., Hellbach, N., Seabrook, T., ... Servais, L. (February 2021). Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Annals of Clinical and Translational Neurology, 8 (2), 359-373. doi:10.1002/acn3.51281 |
 | Mercuri, E., Muntoni, F., Baranello, G., Masson, R., Boespflug-Tanguy, O., Bruno, C., Corti, S., DARON, A., Deconinck, N., Servais, L., Straub, V., Ouyang, H., Chand, D., Tauscher-Wisniewski, S., Mendonca, N., & Lavrov, A. (2021). Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. The Lancet Neurology, 20 (10), 832-841. doi:10.1016/S1474-4422(21)00251-9 Peer Reviewed verified by ORBi |
 | BOEMER, F., Caberg, J.-H., Beckers, P., Dideberg, V., di Fiore, S., Bours, V., Marie, S., Dewulf, J., Marcelis, L., Deconinck, N., Daron, A., Blasco-Perez, L., Tizzano, E., Hiligsmann, M., Lombet, J., Pereira, T., Lopez-Granados, L., Shalchian-Tehran, S., van Assche, V., ... Servais, L. (2021). Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Scientific Reports, 11 (1), 19922. doi:10.1038/s41598-021-99496-2 Peer Reviewed verified by ORBi |
 | Materne, C., Hudon, L., DARON, A., & Demarche, M. (July 2020). Myasthénie auto-immune juvénile. Revue Médicale de Liège, 75 (7-8), 524-528. Peer reviewed |
 | Aragon-Gawinska, K., DARON, A., Ulinici, A., Vanden Brande, L., Seferian, A., Gidaro, T., Scoto, M., Deconinck, N., & Servais, L. (March 2020). Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen. Developmental Medicine and Child Neurology, 62 (3), 310-314. doi:10.1111/dmcn.14412 Peer Reviewed verified by ORBi |
 | Almeida Ribeiro, M., Bouchard, S., Dupuis, G., Daron, A., & Stassart, C. (20 May 2019). Sentiment de présence et symptômes de cybermalaise dans une population d’enfants souffrant de maux de tête chroniques immergés en réalité virtuelle [Poster presentation]. La qualité de vie au cœur des soins de première ligne : évaluations, applications et perspectives de vie, Liège, Belgium. |
 | Annoussamy, M., Lilien, C., Gidaro, T., Gargaun, E., Che, V., Schara, U., Gangfuss, A., D'Amico, A., Dowling, J. J., Darras, B. T., Daron, A., Hernandez, A., de Lattre, C., Arnal, J.-M., Mayer, M., Cuisset, J.-M., Vuillerot, C., Fontaine, S., Bellance, R., ... Servais, L. (16 April 2019). X-linked myotubular myopathy: A prospective international natural history study. Neurology, 92 (16), 1852-e1867. doi:10.1212/WNL.0000000000007319 Peer Reviewed verified by ORBi |
 | Daron, A., DELSTANCHE, S., Dangouloff, T., & Servais, L. (February 2019). Amyotrophie spinale infantile (R)évolution thérapeutique. Revue Médicale de Liège, 74 (2), 82-85. |
 | Aragon-Gawinska, K., Seferian, A. M., DARON, A., Gargaun, E., Vuillerot, C., Cances, C., Ropars, J., Chouchane, M., Cuppen, I., Hughes, I., Illingworth, M., Marini-Bettolo, C., Rambaud, J., Taytard, J., Annoussamy, M., Scoto, M., Gidaro, T., & Servais, L. (October 2018). Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study. Neurology, 91 (14), 1312-e1318. doi:10.1212/WNL.0000000000006281 Peer Reviewed verified by ORBi |
Chabanon, A., Annoussamy, M., DARON, A., Péréon, Y., Cances, C., Vuillerot, C., Goemans, N., Cuisset, J., Laugel, V., Schara, U., Gidaro, T., Seferian, A., Lowes, L., Carlier, P., Hogrel, J., Czech, C., Hermosilla, O., Kwaja, O., & Servais, L. (October 2018). Two years, longitudinal data of the European prospective natural history study of patients with type 2 and 3 spinal muscular atrophy [Poster presentation]. WMS Congress 2018, Mendoza, Argentina. |
Annoussamy, M., Grangé, A., Lilien, C., Chê, V., Duchêne, D., Gidaro, T., Behin, A., Baets, J., D'Amico, A., DARON, A., Bitoun, M., Paradis, K., Thielemans, L., Van Rooijen, S., & Servais, L. (October 2018). Baseline characteristics of patients with centronuclear myopathy due to mutations in DNM2 gene enrolled in a European prospective natural history study [Poster presentation]. WMS Congress 2018, Mendoza, Argentina. |
Aragon-Gawinska, K., Seferian, A., Vanden Brande, L., DARON, A., Ulinici, Deconinck, N., Annoussamy, M., Vuillerot, C., Cances, C., Ropars, J., Chouchane, M., Balintova, Z., Modrzejewska, S., Cuppen, I., Hughes, I., Illingworth, M., Marini-Bettolo, C., White, K., Scoto, M., ... Servais, L. (October 2018). Treatment by nusinersen in spinal muscular atrophy type 1 patients older than 7 months, 14 months follow-up [Poster presentation]. WMS Congress 2018, Mendoza, Argentina. |
Annoussamy, M., Lilien, C., Gidaro, T., Chê, V., Schara, U., D'Amico, A., Dowling, J., Darras, B., DARON, A., Mayer, M., Hernandez, A., Vuillerot, C., Fontaine, S., de Lattre, C., Bellance, R., Biancalana, V., Buj-Bello, A., Hogrel, J., Landy, H., ... NatHis-MTM Study Group. (October 2018). Clinical changes over time in a European and North-American cohort of patients with X-linked Myotubular Myopathy [Poster presentation]. WMS Congress 2018, Mendoza, Argentina. |
Hogrel, J., Annoussamy, M., Chabanon, A., DARON, A., Péréon, Y., Cances, C., Vuillerot, C., Goemans, N., Cuisset, J., Laugel, V., Schara, U., Gargaun, E., Gidaro, T., Seferian, A., Turk, S., Hermosilla, R., Fournier, E., Baudin, P., Carlier, P., & Servais, L. (October 2018). Associations between NMR, electrophysiological, strength and function variables in SMA type 2 and 3 [Poster presentation]. WMS Congress, Mendoza, Argentina. |
 | Chabanon, A., Seferian, A. M., DARON, A., Pereon, Y., Cances, C., Vuillerot, C., De Waele, L., Cuisset, J.-M., Laugel, V., Schara, U., Gidaro, T., Gilabert, S., Hogrel, J.-Y., Baudin, P.-Y., Carlier, P., Fournier, E., Lowes, L. P., Hellbach, N., Seabrook, T., ... Servais, L. (July 2018). Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. PLoS ONE, 13 (7), 0201004. doi:10.1371/journal.pone.0201004 Peer Reviewed verified by ORBi |
LEROY, P., DARON, A., & DEPIERREUX, F. (25 March 2017). Dystonie de type 11 à début précoce [Paper presentation]. 45ème Réunion de la Société Européenne de Neuropédiatrie (2017), Turin, Italy. |
 | DARON, A., DRESSE, M.-F., Hoyoux, C., Tebache, M., MISSON, J.-P., & DEBRAY, F.-G. (2015). Schizencephaly associated with a severe prothrombotic syndrome caused by antithombin III deficiency. Tijdschrift van de Belgische Kinderarts, 17 (1), 109. Peer reviewed |
 | MAGIS, D., Boon, E., Coppola, G., DARON, A., & Schoenen, J. (2012). A novel CACNA1A mutation results in episodic ataxia with migrainous features without headache. Cephalalgia. doi:10.1177/0333102412459572 Peer Reviewed verified by ORBi |
 | Vaessen, S., DARON, A., DUBRU, J.-M., Ebetiuc, I., Leroy, P., & Misson, J.-P. (2012). Aspects neurologiques associés au Syndrome de Down. Tijdschrift van de Belgische Kinderarts, 14 (2), 40-43. Peer reviewed |
 | Mohring, M.-P., Dadoumont, C., DARON, A., Leroy, P., & Misson, J.-P. (2007). Intoxication au CO: Mouvements athétosiques. Journal de Pédiatrie belge. Peer reviewed |
 | Leroy, P., DARON, A., Weerts, E., Born, J.-D., & Misson, J.-P. (2005). Encéphalocéle frontoethimoidale: Encéphalite herpétique comme premier signe d'une méningite récurrente. Revista de Neurologia. Peer Reviewed verified by ORBi |
 | DARON, A., Leroy, P., & Misson, J.-P. (2005). A propos d'un cas d'hémiparésie aigue chez l'enfant. Percentile, 10, 29. Peer reviewed |
Piette, C., DARON, A., Leroy, P., Gougnard, T., & Minon, J.-M. (2005). Intoxicatin à la cyproheptadine: un cas clinique [Paper presentation]. Annual meeting of the French Society of Clinical Toxicology. |